Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Threatening Illness Perception and Associated Factors in Early-stage Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
3-017

Patients with early-stage RRMS experience uncertainty and intense emotions as diagnosis is disclosed. Illness perception at this point can influence levels of adjustment, coping strategies, and patients’ well-being.

The aim of this study was to assess the illness perception and associated factors in early-stage relapsing remitting multiple sclerosis (RRMS) patients.

A multicentre, non-interventional study was conducted. Adult patients with RRMS, disease duration ≤3 years, and Expanded Disability Status Scale (EDSS) score between 0-5.5 were included. The Brief-Illness Perception Questionnaire (B-IPQ) was used to assess patients’ cognitive and emotional illness representation. Patient-reported measures were administered to gather information on different outcomes.

A multivariate logistic regression analysis was performed to assess the association between B-IPQ and demographic, clinical characteristics, and patients’ perspectives.

A total of 189 patients were included (mean age: 36.1±9.4 years, 71.4% female, mean disease duration: 1.4±0.8 years). Median EDSS score was 1.0 (IQR=0.0-2.0).

A proportion of 36.5% (n=69/189) patients had a moderate-to-high threatening illness perception, and 45.5% of patients thought that their MS was caused by psychological factors.

Bivariate analyses suggested that patients were significantly more likely to have a threatening disease perception if they were unemployed, received symptomatic treatment, had a higher EDSS, worse hand dexterity and gait, higher perception of pain, fatigue, symptom severity, hopelessness, and worse perception of their quality of life. Also patients that reported workplace barriers, cognitive complaints, and probable cases of anxiety, depression, and stigma.

Higher EDSS, symptom severity, worse psychological quality of life, perception of stigma, and higher hopelessness-trait were predictors of moderate-to-high threatening illness perception (OR=2.349, 95%CI:1.276-5.130; OR=1.208, 95%CI:1.089-1.364; OR=1.051, 95%CI:1.018-1.089; OR=3.365, 95%CI:1.152-10.796; OR=41.177, 95%CI:6.942-388.825, respectively, all p<0.05).

Threatening illness perceptions are common among patients with early RRMS. Identifying these beliefs and its associated factors and establishing individualized interventions may help patients deal with their condition.
Authors/Disclosures
Tamara Castillo-Trivino, MD, MAS, FAAN (Donostia University Hospital)
PRESENTER
Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol-Myers Squibb. The institution of Dr. Castillo-Trivino has received research support from Basque Government.
Susana Sainz de la Maza Susana Sainz de la Maza has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall, Biogen, Merck, Novartis, Roche and Sanofi-Genzyme.
Rocío Gómez, Other (Roche Farma S.A.) Ms. Gómez has received personal compensation for serving as an employee of Roche Farma Spain, Medical Department.
Mónica Borges Guerra, Other Mrs. Borges Guerra has nothing to disclose.
Jesus Manuel Martin Martinez Jesus Manuel Martin Martinez has nothing to disclose.
Javier Sotoca Fernandez No disclosure on file
Ana María Alonso Torres, MD Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Ana Belen Caminero Rodriguez, MD (C/ Fuentes Claras #1) Dr. Caminero Rodriguez has nothing to disclose.
Laura Borrega Canelo, Sr., MD (HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN) Dr. Borrega Canelo has nothing to disclose.
Jose Luis Sanchez Menoyo, MD (Neurologia - Hospital Galdakao-Usansolo) Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Francisco Barrero-Hernandez, Sr., MD (SAS) Dr. Barrero-Hernandez has nothing to disclose.
Carmen Calles, MD (Grupo 7 Viajes) Dr. Calles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi, Biogen, Roche, Teva, Novartis, Merck. Dr. Calles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Teva, Biogen, Roche, Novartis, Merck.
Luis Brieva Ruiz, MD (Hospital Arnau Vilanova) Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for All comercial companies interested in Multiple Sclerosis. Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Al comercial companies in Multiple Sclerosis. The institution of Dr. Brieva Ruiz has received research support from Carlos III Institut. Madrid. Spain..
Rosario Blasco Quilez (Hospital Puerta De Hierro) Rosario Blasco Quilez has nothing to disclose.
Julio Dotor Garcia-Soto JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck, Biogen, Sanofi-Genzyme, Almirall, Teva, UCB, Novartis.
Maria Campo Amigo Maria Campo Amigo has nothing to disclose.
Laura Navarro Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen idec. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132) Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
Moises Garces Redondo, MD (Hospital Clinico Lozano Blesa) Mr. Garces Redondo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Mr. Garces Redondo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Mr. Garces Redondo has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Almirall. Mr. Garces Redondo has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis.
Olga Carmona, MD Dr. Carmona has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERCK. Dr. Carmona has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for BIOGEN .
Gabaldon Torres Laura, Jr., Other Mrs. Laura has nothing to disclose.
Lucía *use 253857 Forero Lucía Forero has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Lucía Forero has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche .
Mariona Hervas Pujol Mariona Hervas Pujol has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Merk, Bayer, Biogen, Almirall.
Jorge Maurino Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.